NCCN VERSION 2 2015

173 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-98
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
long-term follow-up experience. Clin Drug Investig 2006;26:43-48.
Available at: .
427. Pecherstorfer M, Rivkin S, Body J-J, et al. Long-term safety of
intravenous ibandronic acid for up to 4 years in metastatic breast
cancer: an open-label trial. Clin Drug Investig 2006;26:315-322.
Available at: .
428. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and
safety of zoledronic acid compared with pamidronate disodium in the
treatment of skeletal complications in patients with advanced multiple
myeloma or breast carcinoma: a randomized, double-blind, multicenter,
comparative trial. Cancer 2003;98:1735-1744. Available at:
.
429. Wilkinson GS, Kuo Y-F, Freeman JL, Goodwin JS. Intravenous
bisphosphonate therapy and inflammatory conditions or surgery of the
jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016-
1024. Available at: .
430. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and
selective aromatase inhibitor, versus megestrol acetate in
postmenopausal women with advanced breast cancer: results of
overview analysis of two phase III trials. Arimidex Study Group. J Clin
Oncol 1996;14:2000-2011. Available at:
431. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral
aromatase inhibitor for advanced breast cancer: double-blind
randomized trial showing a dose effect and improved efficacy and
tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-
461. Available at: .
432. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in
metastatic breast cancer after failure of nonsteroidal aromatase
inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-2244. Available at:
.
433. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole
versus tamoxifen as first-line therapy for advanced breast cancer in 668
postmenopausal women: results of the Tamoxifen or Arimidex
Randomized Group Efficacy and Tolerability study. J Clin Oncol
2000;18:3748-3757. Available at:
.
434. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to
tamoxifen as first-line therapy for advanced breast cancer in
postmenopausal women: results of a North American multicenter
randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-
3767. Available at:
435. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing
exemestane with tamoxifen as first-line hormonal treatment of
metastatic breast cancer in postmenopausal women: the European
Organisation for Research and Treatment of Cancer Breast Cancer
Cooperative Group. J Clin Oncol 2008;26:4883-4890. Available at:
.
436. Vergote I, Bonneterre J, Thurlimann B, et al. Randomised study of
anastrozole versus tamoxifen as first-line therapy for advanced breast
cancer in postmenopausal women. Eur J Cancer 2000;36 Suppl 4:S84-
85. Available at:
437. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for
treatment of advanced breast cancer in postmenopausal women.
Cochrane Database Syst Rev 2009. Available at:
.
438. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of
fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for
advanced breast cancer: results from the FIRST study. J Clin Oncol
2009;27:4530-4535. Available at:
.
439. Robertson JF, Llombart-Cussac A, Rolski J, et al. A comparison of
fulvestrant 500 mg with anastrazole as first-line treatment for advanced